PL373526A1 - Sposób wytwarzania głównego hipoalergicznego alergenu pyłku brzozy rBet v 1 - Google Patents

Sposób wytwarzania głównego hipoalergicznego alergenu pyłku brzozy rBet v 1

Info

Publication number
PL373526A1
PL373526A1 PL03373526A PL37352603A PL373526A1 PL 373526 A1 PL373526 A1 PL 373526A1 PL 03373526 A PL03373526 A PL 03373526A PL 37352603 A PL37352603 A PL 37352603A PL 373526 A1 PL373526 A1 PL 373526A1
Authority
PL
Poland
Prior art keywords
birch pollen
pollen allergens
major birch
rbet
hypoallergenic major
Prior art date
Application number
PL03373526A
Other languages
English (en)
Other versions
PL206709B1 (pl
Inventor
Roland Suck
Helmut Fiebig
Oliver Cromwell
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27763342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373526(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL373526A1 publication Critical patent/PL373526A1/pl
Publication of PL206709B1 publication Critical patent/PL206709B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL373526A 2002-02-27 2003-02-07 Sposób wytwarzania i sposób obniżania aktywności IgE głównego hipoalergicznego alergenu pyłku brzozy rBet v 1, główny hipoalergiczny alergen pyłku brzozy rBet v 1uzyskiwany takim sposobem i jego zastosowanie jako leku oraz kompozycja farmaceutyczna zawierająca taki główny alergen PL206709B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004567 2002-02-27

Publications (2)

Publication Number Publication Date
PL373526A1 true PL373526A1 (pl) 2005-09-05
PL206709B1 PL206709B1 (pl) 2010-09-30

Family

ID=27763342

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373526A PL206709B1 (pl) 2002-02-27 2003-02-07 Sposób wytwarzania i sposób obniżania aktywności IgE głównego hipoalergicznego alergenu pyłku brzozy rBet v 1, główny hipoalergiczny alergen pyłku brzozy rBet v 1uzyskiwany takim sposobem i jego zastosowanie jako leku oraz kompozycja farmaceutyczna zawierająca taki główny alergen

Country Status (12)

Country Link
US (2) US20050123568A1 (pl)
EP (1) EP1478662B2 (pl)
JP (1) JP4343702B2 (pl)
AT (1) ATE443716T1 (pl)
AU (1) AU2003208817A1 (pl)
CA (1) CA2477409C (pl)
DE (1) DE50311945D1 (pl)
ES (1) ES2333951T5 (pl)
PL (1) PL206709B1 (pl)
PT (1) PT1478662E (pl)
RU (1) RU2311424C2 (pl)
WO (1) WO2003072601A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
JP5279238B2 (ja) * 2006-11-16 2013-09-04 森川健康堂株式会社 血圧降下作用を有する花粉の製造方法
EP2523685A1 (de) * 2010-01-14 2012-11-21 Merck Patent GmbH VARIANTEN DER GRUPPE 5-ALLERGENE DER SÜßGRÄSER MIT REDUZIERTER ALLERGENITÄT DURCH MUTAGENESE VON PROLINRESTEN
EP2974741A1 (en) * 2014-07-16 2016-01-20 Stallergenes Composition of allergen extracts having reduced toxicity and method of production thereof
AU2017279647B2 (en) 2017-02-15 2022-05-26 Euroimmun Medizinische Labordiagnostika Ag An improved assay for the diagnosis of peanut allergy
RU2761431C9 (ru) 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1691754A1 (ru) * 1989-07-31 1991-11-15 МГУ им.М.В.Ломоносова Способ проведени точечного иммуноферментного анализа
PL194804B1 (pl) * 1998-03-16 2007-07-31 Alk Abello As Zrekombinowany alergen, sposób przygotowywania zrekombinowanego alergenu, kompozycja farmaceutyczna oraz zastosowanie zrekombinowanego alergenu do przygotowywania leku do wywoływania odpowiedzi immunologicznej u osobnika i do przygotowywania leku do leczenia, zapobiegania lub osłabiania reakcji alergicznych
DE10044360A1 (de) * 2000-09-08 2002-03-21 Merck Patent Gmbh Verfahren zur Aufreinigung von rekombinanten als unlösliche Aggregate exprimierte Proteinen

Also Published As

Publication number Publication date
CA2477409C (en) 2015-01-27
US9441021B2 (en) 2016-09-13
EP1478662B1 (de) 2009-09-23
PL206709B1 (pl) 2010-09-30
US20050123568A1 (en) 2005-06-09
JP4343702B2 (ja) 2009-10-14
EP1478662A1 (de) 2004-11-24
WO2003072601A8 (de) 2005-08-18
RU2311424C2 (ru) 2007-11-27
EP1478662B2 (de) 2017-07-05
AU2003208817A1 (en) 2003-09-09
US20090069236A1 (en) 2009-03-12
JP2005536454A (ja) 2005-12-02
CA2477409A1 (en) 2003-09-04
ES2333951T3 (es) 2010-03-03
DE50311945D1 (de) 2009-11-05
ATE443716T1 (de) 2009-10-15
ES2333951T5 (es) 2017-11-16
RU2004129282A (ru) 2005-06-10
PT1478662E (pt) 2009-12-29
WO2003072601A1 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
EP1585966A3 (en) METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2004034988A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2004009590A8 (de) 4-aminosubstituierte pyrimidinderivate
AU2003231344A1 (en) Selective nerve fiber stimulation for treating heart conditions
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
TW200513468A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
TW200612985A (en) Immunoglobulins
WO2004041258A3 (fr) Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
GB0213625D0 (en) Multi-channel bioresorbable nerve regeneration conduit and process for preparing the same
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
MY146238A (en) Prodrugs of excitatory amino acids
PL373526A1 (pl) Sposób wytwarzania głównego hipoalergicznego alergenu pyłku brzozy rBet v 1
EP2450041A3 (en) Improved testosterone gel and method of use
EP1565209A4 (en) PRECURSOR N-ACETYLGALACTOSAMINE-4-SULFATASE, TREATMENT METHOD USING THIS ENZYME AND METHOD FOR PRODUCING AND CLEANING THIS ENZYME
MXPA06003381A (es) Beta aminoacidos terapeuticos.
PL1817330T3 (pl) Pochodne alergenów białkowych
EP1608352A4 (en) POLYAMINE COMPOUNDS FOR THE TREATMENT OF CHEMOKINE-RECEPTOR INDUCED DISEASES
WO2005040338A3 (en) Constrained alkaloid immunogens and antibodies and uses thereof
WO2006036213A3 (en) The use of gammaglobulin for the treatment of periodontal disease
WO2003087345A3 (en) Stimulation of nerve cell regeneration